Previous 10 | Next 10 |
The FDA has designated Orphan Drug status to Acceleron Pharma's (XLRN) ACE-1334 for the treatment of systemic sclerosis, an autoimmune rheumatic disease characterized by excessive production and accumulation of collagen, called fibrosis, in the skin and internal organs.The Company intend...
– Company plans to initiate Phase 1b/Phase 2 trial in patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD) in 2021 – – ACE-1334 previously received Fast Track designation from the FDA – Acceleron Pharma Inc. (Nas...
Biotech stocks should be on investors’ radars due to the COVID-19 pandemic. A few of them have also made significant progress in developing a vaccine or a treatment for the deadly infection. Besides, biotech companies are also playing a crucial role in developing treatments for other d...
Acceleron Pharma ([[XLRN]] -1.8%) announces new data from two Phase 2 clinical trials, SPECTRA and PULSAR, evaluating sotatercept in patients with pulmonary arterial hypertension ((PAH)).Preliminary results from 10 participants in SPECTRA showed that treated patients experienced substantial i...
– Treatment with sotatercept in first set of patients in the ongoing SPECTRA Phase 2 trial was associated with substantial improvements in hemodynamics, exercise tolerance and exercise capacity at week 24 – – Sotatercept was generally well tolerated, consi...
– Treatment with sotatercept in the ongoing PULSAR Phase 2 trial was associated with improvements in cardiac and pulmonary function at week 24 – – Presentation of echocardiography data from the PULSAR trial received AHA’s “Cardiopulmonary Bes...
Geron's only therapeutic candidate currently undergoing a Phase III trial has superior efficacy. The consensus has underestimated its sales potential, and the shares have yet to reach the 2018 high. Subject to regulatory approvals, a swift achievement of the fullest sales potentia...
– Presentation of cardiac and pulmonary function data from the ongoing PULSAR Phase 2 trial receives AHA’s “Cardiopulmonary Best Abstract” Award – – AHA sessions to include data from the ongoing SPECTRA Phase 2 trial – &...
Acceleron Pharma Inc. (XLRN) Q3 2020 Earnings Conference Call November 05, 2020 05:00 PM ET Company Participants Jamie Bernard - Associate Director of Investor Relations Habib Dable - Chief Executive Officer Kevin McLaughlin - Chief Financial Officer Jay Backstrom - Head of Research & Dev...
The following slide deck was published by Acceleron Pharma Inc. in conjunction with their 2020 Q3 earnings call. For further details see: Acceleron Pharma Inc. 2020 Q3 - Results - Earnings Call Presentation
News, Short Squeeze, Breakout and More Instantly...
Acceleron Pharma Inc. Company Name:
XLRN Stock Symbol:
NASDAQ Market:
Acceleron Pharma Inc. Website:
Believes Transaction Comes at the Wrong Time, With the Wrong Price, and Following the Wrong Process Remains Confident in Company’s Standalone Opportunities – Given Strong Momentum and Near-Term Inflection Point Coming from Phase 3 Data Stands Ready to Hel...
In September, Merck (NYSE: MRK) announced plans to acquire Acceleron Pharma (NASDAQ: XLRN) for $11.5 billion. However, the big drugmaker recently revealed that it withdrew a key regulatory filing document related to the transaction. In this Motley Fool Live video ...